Company Overview and News
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
HDFC 500010 HDFC
Mumbai: HDFC Bank Ltd, the world’s most expensive major lender, is considering relying entirely on the Indian market for a share sale that could raise as much as Rs 15,500 crore ($2.3 billion), people with knowledge of the matter said.
523405 DGLD MS.PRE MS.PRF MS.PRG 532636 IIFL HDFC MS.PRA CS UGLD HDFCBANK MS 500010 JMFINANCIL DSLV EDELWEISS VIIX CSSLF VIIZ 532922 CSGKF MS.PRI MS.PRK HDB 500180 ZIV USLV TVIX HDFC XIV
MUMBAI/HONG KONG (June 18): HDFC Bank Ltd, the world’s most expensive major lender, is considering relying entirely on the Indian market for a share sale that could raise as much as 155 billion rupees (US$2.3 billion), people with knowledge of the matter said.
HDB 500180 HDFCBANK HDFC 500010 HDFC
Podcast | An evening walk down Dalal Street: Sensex recoups losses; Nifty holds 10,800 for 4th day
IOC 500325 HDFC 532960 532482 532480 BJJQY 500570 500010 RLNIY ASHOKLEY SBAZ AXB ALBK 532505 YYBKY 530965 AKLD AXBA BAJAJFINSV BAJFINANCE TCS HDFC AKLS ANDHRABANK DB PQRTY RELIANCE KTKBANK 532418 532978 533155 TTNQY JUBLFOOD IDBLZ 532215 GRANULES 532540 532187 AXISBANK RIGD JBLWY 500477 TATAMOTORS 500034 VALIANT YESBANK UBNC INDUSINDBK IBVENTURES IBN 532648 PETRONET 532522 AXBKY 532652 ICICIBANK 532174 526775 UCOBANK TTM
On account of the rising dollar prices, the Indian rupee has been trending down since the beginning of 2018. On May 7, the currency went down to its lowest in 15 months and was trading at 67.13 against the dollar.
500325 RELIANCE RIGD INFY HDFC 500010 HDFC RLNIY
New Delhi : Sebi on Friday proposed a slew of changes to public issue norms, including shorter time period for price band announcement and lesser disclosures about group companies at the time of IPOs.
HDFC 500010 HDFC
Market Closing: Benchmark indices closed sharply lower on Friday, with the Sensex falling 187.76 points to 34,915.38 and the Nifty declining 61.40 points to 10,618.30.
BAJAJ-AUTO 500408 500325 ATB HDFC ASIANPAINT JSWENERGY JUSTDIAL AMBUY 506590 PHILIPCARB 500412 500010 RLNIY GRUH AXB YYBKY 513375 CASTROLIND AXBA FORTIS 534809 PCJEWELLER HDFC 500820 500425 533150 RELIANCE 532977 BHRQY AMBUJACEM 532215 511288 CSLQY 532541 535648 AXISBANK RIGD BHARTIARTL 500870 YESBANK NIITTECH CARBORUNIV HINDALCO 532648 GRHFY HEXAWARE 532129 532843 533148 AXBKY TIRUMALCHM 532454 HNDNF GODREJPROP TATAELXSI JSTQY 500440
Earnings: Ambuja Cements has reported standalone profit at Rs 271.8 crore for the quarter ended March 2018, a growth of 10.3 percent over Rs 246.5 crore reported in year-ago.
BAJAJ-AUTO 500325 500820 500425 533150 RELIANCE ATB 532977 HDFC BHRQY AMBUJACEM ASIANPAINT 532215 532541 AMBUY AXISBANK 506590 RIGD PHILIPCARB 500412 BHARTIARTL 500010 RLNIY NIITTECH YESBANK HINDALCO CARBORUNIV AXB 532648 YYBKY 513375 AXBKY TIRUMALCHM HNDNF 532454 AXBA GODREJPROP 534809 PCJEWELLER HDFC 500440
HDFC or the Housing Development Finance Corporation reported a 39 percent jump in net profit to Rs 2,846 crore for the fourth quarter ending March 2018, exceeding expectations despite an increase in the provisions.
AXBKY AXBA ICICIBANK AXB AXISBANK 532174 IBN HDFC 500010 HDFC 532215 SBAZ
The boards of directors of Housing Development Finance Corporation, Dewan Housing Finance and India Glycols will meet on Monday to consider fund-raising plans. The board of India Glycols will also consider the result for the quarter and full-year ended March 2018. HDFC and Dewan Housing will consider fund raising by way of further public issue of secured non-convertible debentures. The board of HDFC will also consider increase in the overall borrowing powers.
YESBANK DHFL INDIAGLYCO 511072 500201 532648 HDFC YYBKY 500010 HDFC
New Delhi: Leading mutual fund house HDFC Asset Management Company (AMC) on Tuesday reported a 31% jump in net profit at Rs722.61 crore in 2017-18 compared to Rs550.24 crore in the previous financial year.
HDFC 500010 HDFC
Our Bureau HDFC Asset Management Co on Monday reported a 31 per cent jump in profit after tax at ₹722.61 crore for the fiscal 2017-18. Last year, the AMC had reported a net profit of ₹550.24 crore.
532505 HDFC UCOBANK 500570 500010 HDFC TATAMOTORS TTM
Eight of the 10 most valued Indian companies together added Rs 83,672 crore to their market valuation for last week, with IT major Tata Consultancy Services (TCS) leading the pack.
500325 RELIANCE HINDUNILVR HDFC TTNQY MRZUY 532500 532540 HDB MARUTI 500180 RIGD 500696 HDFCBANK TCS 500010 HDFC RLNIY SBAZ
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...